EYPT - Company ID 0001314102
The table below shows EyePoint Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$80.55M | -$53.12M | -$31.17M | -$16.84M | -$20.16M | -$15.10M |
| Capital expenditure | $997.00K | $276.00K | $1.19M | $484.00K | $149.00K | $0.00 |
| Investing cash flow | $59.05M | $39.52M | $20.81M | $32.09M | -$56.44M | $0.00 |
| Dividends paid | - | - | - | - |
EyePoint Pharmaceuticals, Inc. reported operating cash flow of -$240.11M for fiscal year 2025. That is down 90.2% from -$126.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$16.32M (FY 2016) to -$240.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$2.61M | -$951.00K | $115.00K | -$5.12M | -$448.00K | $108.77M |